ArticleThe American journal of pathology2000
Genetic profile of gliosarcomas.
Article in The American journal of pathology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 235 citations in OpenAlex.
- Clinical and molecular features of primary gliosarcoma with digital spatial whole-transcriptome analysis of glial and mesenchymal components.Brain pathology (Zurich, Switzerland) · 2026Article
- Review
- Gliosarcoma of the craniovertebral junction with loss of H3K27me3: a case report with molecular profiling.Brain tumor pathology · 2026Article
- Loss of meningothelial identity and mesenchymal fate switching in NF2-mutant meningiomas.Acta neuropathologica · 2026Article
- Distal noncontiguous recurrence and sarcomatous transformation of glioblastoma with stable molecular profile: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Uncommon territory: The clinical and molecular profile of metastatic gliomas.Neuro-oncology · 2026Article
- Rare osseous mastoid invasion of secondary gliosarcoma: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Molecular characterization of gliosarcoma reveals prognostic biomarkers and clinical parallels with glioblastoma.Journal of neuro-oncology · 2025Article
- Sarcomatous transformation of IDH-mutant astrocytoma matching to methylation class oligosarcoma following embolization, a case report.Acta neuropathologica communications · 2024Article
- Gliosarcoma: A Multi-Institutional Analysis on Clinical Outcomes and Prognostic Factors.Cancer medicine · 2024Article
- Metastatic glioblastoma to the lungs: a case report and literature review.CNS oncology · 2024Review
- Molecular signature of stem-like glioma cells (SLGCs) from human glioblastoma and gliosarcoma.PloS one · 2024Article
- Primary Intracranial Gliosarcoma: Is It Really a Variant of Glioblastoma? An Update of the Clinical, Radiological, and Biomolecular Characteristics.Journal of clinical medicine · 2023Review
- Deep molecular tracking over the 12-yr development of endometrial cancer from hyperplasia in a single patient.Cold Spring Harbor molecular case studies · 2023Article
- RAR-Dependent and RAR-Independent RXR Signaling in Stem-like Glioma Cells.International journal of molecular sciences · 2023Article
- Pediatric gliosarcoma, a rare central nervous system tumor in children: Case report and literature review.Heliyon · 2023Article
- An autopsy case of primary gliosarcoma with multiple extracranial metastases: pathology after administration of bevacizumab and genetic profile.Nagoya journal of medical science · 2023Article
- A rare, giant, lateral intraventricular gliosarcoma.Radiology case reports · 2023Article
- Primary gliosarcoma with widespread extracranial metastases-spatiotemporal morphological variation.Chinese neurosurgical journal · 2022Article
- Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.Journal of neuro-oncology · 2022Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are distinct genetic pathways leading to the glioblastoma, the most malignant astrocytic brain tumor. Primary (de novo) glioblastomas develop in older patients and are characterized by epidermal growth factor (EGF) receptor amplification/overexpression, p16 deletion, and PTEN mutations, whereas secondary glioblastomas that progressed from low-grade or anaplastic astrocytoma develop in younger patients and frequently contain p53 mutations. In this study, we assessed the genetic profile of gliosarcoma, a rare glioblastoma variant characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation. Single-strand conformation polymorphism followed by direct DNA sequencing revealed p53 mutations in five of 19 gliosarcomas (26%) and PTEN mutations in seven cases (37%). Homozygous p16 deletion was detected by differential polymerase chain reaction in seven (37%) gliosarcomas. The overall incidence of alterations in the Rb pathway (p16 deletion, CDK4 amplification, or loss of pRb immunoreactivity) was 53%, and these changes were mutually exclusive. Coamplification of CDK4 and MDM2 was detected in one gliosarcoma. None of the gliosarcomas showed amplification or overexpression of the EGF receptor. Thus gliosarcomas exhibit a genetic profile similar to that of primary (de novo) glioblastomas, except for the absence of EGFR amplification/overexpression. Identical PTEN mutations in the gliomatous and sarcomatous tumor components were found in two cases. Other biopsies contained p16 deletions, an identical p53 mutation, or coamplification of MDM2 and CDK4 in both tumor areas. This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.